No Data
No Data
No Data
No Data
No Data
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
PDF Version BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company"), a targeted oncology company forging new territory in patient-directed cancer treatmen
Ikena OncologyApr 10 12:00
The Analyst Landscape: 4 Takes On Ikena Oncology
4 analysts have expressed a variety of opinions on Ikena Oncology (NASDAQ:IKNA) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below offers a condensed vie
BenzingaMar 19 20:01
HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $11 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology with a Buy and maintains $11 price target.
Analyst UpgradesMar 19 19:05
Ikena Oncology's IK-595: A Promising Contender in the MAPK-Driven Tumor Space
TipRanksMar 19 18:27
Ikena Oncology's Promising Drug Pipeline Merits a Buy Rating
TipRanksMar 13 06:05
Ikena Oncology: Q4 Earnings Insights
Ikena Oncology (NASDAQ:IKNA) reported its Q4 earnings results on Tuesday, March 12, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsIkena Oncology beat estimated ear
BenzingaMar 13 05:05
No Data
No Data